Molecular Modeling and Site-Directed Mutagenesis Studies of a Phorbol Ester-Binding Site in Protein Kinase C

1996 ◽  
Vol 39 (13) ◽  
pp. 2541-2553 ◽  
Author(s):  
Shaomeng Wang ◽  
Marcelo G. Kazanietz ◽  
Peter M. Blumberg ◽  
Victor E. Marquez ◽  
G. W. A. Milne
1995 ◽  
Vol 270 (37) ◽  
pp. 21852-21859 ◽  
Author(s):  
Marcelo G. Kazanietz ◽  
Shaomeng Wang ◽  
George W. A. Milne ◽  
Nancy E. Lewin ◽  
Howard L. Liu ◽  
...  

1999 ◽  
Vol 42 (18) ◽  
pp. 3436-3446 ◽  
Author(s):  
Shaomeng Wang ◽  
Ming Liu ◽  
Nancy E. Lewin ◽  
Patricia S. Lorenzo ◽  
Dipak Bhattacharrya ◽  
...  

1993 ◽  
Vol 268 (5) ◽  
pp. 3494-3498
Author(s):  
K.M. Lounsbury ◽  
B. Schlegel ◽  
M. Poncz ◽  
L.F. Brass ◽  
D.R. Manning

1998 ◽  
Vol 330 (3) ◽  
pp. 1277-1282 ◽  
Author(s):  
Thierry DUBOIS ◽  
Jean-Paul MIRA ◽  
Denis FELIERS ◽  
Egle SOLITO ◽  
Françoise RUSSO-MARIE ◽  
...  

In this study, we assessed the role of annexin V, a Ca2+-dependent phospholipid-binding protein, as a regulator of protein kinase C (PKC) and characterized its mechanism of inhibition. Several mutants obtained by oligonucleotide site-directed mutagenesis were tested in vitro on PKC activity in cytosolic fractions from Jurkat cells and on purified PKCα. Annexin V inhibited phosphorylation of annexin II by endogenous PKC and phosphorylation of myelin basic protein by PKCα. In both systems, the use of single Ca2+-binding-site mutants of annexin V led to a partial reversal of inhibition, and the Ca2+-binding site located in the first domain of annexin V was found to have the most important role. An increase in the number of mutated Ca2+-binding sites led to a greater loss of inhibition. These results corroborated those showing the progressive loss of binding of these mutants to phospholipid liposomes. In conclusion, we show that PKC inhibition by annexin V is the consequence of a mechanism involving phospholipid sequestration by annexin V, and that the Ca2+-binding site located in domain 1 of annexin V plays a predominant role in this process. In addition, we show that the R122AIK site, which may act analogously to a PKC-inhibitory pseudosubstrate site, is not involved in PKC inhibition, and that a peptide corresponding to the C-terminal tail of annexin V inhibits PKC activity but to a lesser extent than annexin V itself.


Sign in / Sign up

Export Citation Format

Share Document